Patients with type 1 diabetes (T1D) also respond to SGLT2 inhibitors with significantly lower A1C levels, body weight, and blood pressure, and with an increased percentage of time that their blood glucose levels are within the acceptable range of 70 to 180 mg/dL, namely the time in range (TIR) (9–17). This evidence concerns the gene SLC5A2 and type 1 diabetes mellitus.